Basant Ebaid Clinical Oncology Society of Australia Annual Scientific Meeting 2022

Abstracts this author is presenting:

• Characterization and management of adverse reactions (ARs) in patients with advanced renal cell carcinoma (aRCC) receiving Lenvatinib + Pembrolizumab (CLEAR Study) — Poster session 1
• Updated efficacy of lenvatinib (LEN) + pembrolizumab (PEMBRO) versus sunitinib (SUN) in patients with advanced renal cell carcinoma (aRCC) in the CLEAR study — Poster session 1